







# DBPR807: A CXCR4-Targeted Antagonist

Institute of Biotechnology and Pharmaceutical Research  
National Health Research Institutes, Taiwan  
2023

# Effects of DBPR807 in Combination with Sorafenib in HCC


DBPR807 alone or combination show superior efficacy as compared to **sorafenib** or **AMD3100** alone.




Proc Natl Acad Sci U S A.  
2021; 118(13): e2015433118

# Effect of DBPR807 in Combination With Anti-PD-1 in HCC

DBPR807 combination shows superior efficacy as compared to **anti-PD-1 alone**.





# DBPR807 Shows Superior Efficacy as Compared to AMD11070 in HCC





# Injection Twice/Week (IV or SC) in HCC

*In vivo*



# DBPR807 Ameliorates Recovery of Cardiac Function after IRI in Mini-pig



DBPR807 (3 mg/kg, IV)

Int. J. Mol. Sci. 2022; 23:11730.